SomaLogic

SomaLogic is a privately-owned American protein biomarker discovery and clinical diagnostics company which monitors health and disease through the analysis of protein concentration changes in biological samples. It has developed the SOMAscan platform that allows scientists and researchers to identify protein biomarkers for diseases and conditions, and apply them to drug and diagnostic research and development. The hypothesis behind the analysis is that different diseases and conditions each have novel protein profiles, including in early stages of onset. As of 2017, the commercial version of the SOMAscan platform could identify and quantify 4,200 protein analytes simultaneously. The platform is based on modified-aptamer binding technology (SOMAmers - Slow-Offrate Modified Aptamers) that bind to their respective target proteins in order to determine their presence and quantity in a sample.